VanEck Associates
EVH icon

VanEck Associates’s Evolent Health EVH Stock Holding History

VanEck Associates’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,703
Closed -$23K – 1442
2025
Q3 		$23K Buy
2,703
+288
+12% +$2.79K ﹤0.01% 1369
2025
Q2 		$27K Buy
2,415
+249
+11% +$2.29K ﹤0.01% 1345
2025
Q1 		$21K Buy
2,166
+133
+7% +$1.34K ﹤0.01% 1335
2024
Q4 		$23K Buy
2,033
+677
+50% +$11.9K ﹤0.01% 1333
2024
Q3 		$30K Sell
1,356
-677
-33% -$17.4K ﹤0.01% 1300
2024
Q2 		$39K Sell
2,033
-345
-15% -$8.81K ﹤0.01% 1302
2024
Q1 		$78K Buy
2,378
+61
+3% +$1.95K ﹤0.01% 1249
2023
Q4 		$77K Buy
2,317
+222
+11% +$6.28K ﹤0.01% 1258
2023
Q3 		$57K Buy
2,095
+323
+18% +$8.98K ﹤0.01% 1272
2023
Q2 		$54K Sell
1,772
-264
-13% -$8.54K ﹤0.01% 1299
2023
Q1 		$66K Buy
2,036
+99
+5% +$3.13K ﹤0.01% 1288
2022
Q4 		$54K Buy
+1,937
New +$55.5K ﹤0.01% 1309

Other funds holding EVH

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VanEck Associates's EVH Position: Q4 2025 in Review

VanEck Associates sold out of Evolent Health (EVH) in Q4 2025, closing a stake of 2,703 shares — an estimated $23K sold.

VanEck Associates first reported a position in EVH in Q4 2022 and held it in 12 quarters. The position peaked at $78K in Q1 2024. 215 funds tracked by Wall St. Rank hold EVH as of Q4 2025.

  • VanEck Associates reported no remaining Evolent Health position as of Q4 2025 after selling out during the quarter.
  • VanEck Associates sold 2,703 Evolent Health shares in Q4 2025, an estimated $23K.
  • VanEck Associates first reported a position in Evolent Health in Q4 2022 and held it in 12 quarters.
  • VanEck Associates's Evolent Health position peaked at $78K in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Evolent Health as of Q4 2025.

Based on VanEck Associates's 13F filing for Q4 2025, filed 13 Feb 2026.